Market Overview

Deutsche Bank Sees Achillion, Arrowhead As Potential Takeover Targets

Related ACHN
Achillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside
Benzinga's Top Initiations

Achillion Pharmaceuticals (NASDAQ: ACHN) and Arrowhead Research (NASDAQ: ARWR) were up sharply Tuesday after an analyst said the pair of drug development companies could become takeover targets.

"If you want to compete with Gilead, you have to buy Achillion," Deutsche Bank's Robyn Karnauskas said on CNBC. "We think that's one take-out target."

Karnauskas noted Achillion's pipeline has promising treatments for hepatitis.

A similar appraisal of Achillion came Monday from UBS's Andrew Peters, who highlighted "a scarcity of de-risked assets."

Speculation about the acquisition of development-stage drug companies has been rife after InterMune (NASDAQ: ITMN) agreed to an $8.3 billion buyout by Roche on Sunday.

Kanauskas appearing on CNBC's "Fast Money" program Monday evening, also said Arrowhead Research "may be attractive" if it releases positive data for its hepatitis drug later this autumn,

Achillion traded recently at $11.65, up eight percent; Arrowhead traded at $15.13, up 12.6 percent.

Latest Ratings for ACHN

Jul 2016Chardan CapitalInitiates Coverage onSell
Jul 2016JMP SecuritiesUpgradesMarket PerformMarket Outperform
May 2016Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color CNBC News Dividends Intraday Update Analyst Ratings Media


Related Articles (ACHN + ARWR)

View Comments and Join the Discussion!